BioSpace News Archive

Aptorum Group Limited is pleased to announce that the United States Food and Drug Administration (FDA) Office has granted Orphan Drug Designation to SACT-1, a repurposed small molecule compound for the treatment of patients with Neuroblastoma.

Stryker Announces First Patient Case Using New Tornier Perform ® Patient-Matched Primary Reversed Glenoid.

Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today announced that David Baker, President and Chief Executive Officer will present at the Virtual Investor 2022 Top Picks Conference on Tuesday, January 25, 2022 at 9:00 AM ET.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), has announced the results of two large scale clinical studies, which show that the company’s Nu.Q® assays, when used in conjunction with the Fecal Immunochemical Test (FIT), can detect colorectal cancer and all high-risk advanced adenomas in symptomatic patients, and thereby reduce unnecessary colonoscopies.

Simulations Plus, Inc. (Nasdaq: SLP), today announced a new funded collaboration with a large pharmaceutical company to modify the GastroPlus® Advanced Compartmental Absorption and Transit (ACAT™) model in support of ongoing research programs for the treatment of gastrointestinal diseases.

Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced the publication of the landmark SMART study in the American Journal of Obstetrics and Gynecology (AJOG), one of the world’s leading Obstetrics and Gynecology medical journals.

enVVeno Medical Corporation announced that Robert Berman, Chief Executive Officer of enVVeno, will present at the Virtual Investor 2022 Top Picks Conference on Tuesday, January 25, 2022 at 1:00 PM ET.

Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, “The Effectiveness of CS Reducer for the Treatment of Refractory Angina – a Meta-Analysis” in the Canadian Journal of Cardiology.

HanAll Biopharma (KRX: 009420.KS) announced today that it achieved 101.6 billion won in sales in 2021, a 15% increase from the previous year.

Rockley Photonics Holdings Limited (NYSE: RKLY) (“Rockley”), a global leader in photonics-based health monitoring and communications solutions, today announced that the company has successfully completed the first stage of its human studies examining the measurement of blood pressure using Rockley’s biomarker sensing platform.